Literature DB >> 26313462

Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study.

Kathryn Puxty1, Philip McLoone2, Tara Quasim1, Billy Sloan2, John Kinsella1, David S Morrison2.   

Abstract

IMPORTANCE: Critical illness may be a potential determinant of cancer outcomes and geographic variations, but its role has not been described before.
OBJECTIVE: To determine the incidence of admission to intensive care units (ICUs) within 2 years following cancer diagnosis. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective observational study using cancer registry data in 4 datasets from 2000 to 2009 with linked ICU admission data from 2000 to 2011, in the West of Scotland region of the United Kingdom (population, 2.4 million; all 16 ICUs within the region). All 118,541 patients (≥16 years) diagnosed as having solid (nonhematological) cancers. Their median age was 69 years, and 52.0% were women. MAIN OUTCOMES AND MEASURES: Demographic and clinical variables associated with admission to an ICU and death in an ICU.
RESULTS: A total of 118,541 patients met the study criteria. Overall, 6116 patients (5.2% [95% CI, 5.0%-5.3%]) developed a critical illness and were admitted to an ICU within 2 years. Risk of critical illness was highest at ages 60 to 69 years and higher in men. The cumulative incidence of critical illness was greatest for small intestinal (17.2% [95% CI, 13.3%-21.8%]) and colorectal cancers (16.5% [95% CI, 15.9%-17.1%]). The risk following breast cancer was low (0.8% [95% CI, 0.7%-1.0%]). The percentage who died in ICUs was 14.1% (95% CI, 13.3%-15.0%), and during the hospital stay, 24.6% (95% CI, 23.5%-25.7%). Mortality was greatest among emergency medical admissions and lowest among elective surgical patients. The risk of critical illness did not vary by socioeconomic circumstances, but mortality was higher among patients from deprived areas. CONCLUSIONS AND RELEVANCE: In this study, about 1 in 20 patients experienced a critical illness resulting in ICU admission within 2 years of cancer diagnosis. The associated high mortality rate may make a significant contribution to overall cancer outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 26313462     DOI: 10.1001/jamaoncol.2015.2855

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  29 in total

Review 1.  What are the ethical aspects surrounding intensive care unit admission in patients with cancer?

Authors:  Jean-Philippe Rigaud; Audrey Large; Nicolas Meunier-Beillard; Stéphanie Gélinotte; Pierre-Louis Declercq; Fiona Ecarnot; Auguste Dargent; Jean-Pierre Quenot
Journal:  Ann Transl Med       Date:  2017-12

2.  Palliative care should be extended to the intensive care unit cancer patients.

Authors:  François Vincent; Laurent Chapuis; Soufia Ayed; Abdelaziz Bouguerba; Sondes Yaacoubi; Caroline Bornstain
Journal:  Support Care Cancer       Date:  2017-03-10       Impact factor: 3.603

3.  Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study.

Authors:  Elie Azoulay; Peter Pickkers; Marcio Soares; Anders Perner; Jordi Rello; Philippe R Bauer; Andry van de Louw; Pleun Hemelaar; Virginie Lemiale; Fabio Silvio Taccone; Ignacio Martin Loeches; Tine Sylvest Meyhoff; Jorge Salluh; Peter Schellongowski; Katerina Rusinova; Nicolas Terzi; Sangeeta Mehta; Massimo Antonelli; Achille Kouatchet; Andreas Barratt-Due; Miia Valkonen; Precious Pearl Landburg; Fabrice Bruneel; Ramin Brandt Bukan; Frédéric Pène; Victoria Metaxa; Anne Sophie Moreau; Virginie Souppart; Gaston Burghi; Christophe Girault; Ulysses V A Silva; Luca Montini; François Barbier; Lene B Nielsen; Benjamin Gaborit; Djamel Mokart; Sylvie Chevret
Journal:  Intensive Care Med       Date:  2017-09-25       Impact factor: 17.440

4.  Challenging decision: ICU admission of critically ill elderly solid tumor patients.

Authors:  Mustafa Benekli
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  Management of superior vena cava syndrome in critically ill cancer patients.

Authors:  Sarah Morin; Adeline Grateau; Danielle Reuter; Eric de Kerviler; Constance de Margerie-Mellon; Cédric de Bazelaire; Lara Zafrani; Benoit Schlemmer; Elie Azoulay; Emmanuel Canet
Journal:  Support Care Cancer       Date:  2017-08-24       Impact factor: 3.603

Review 6.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

7.  Characteristics and outcomes of patients with solid tumors receiving chemotherapy in the intensive care unit.

Authors:  David J Shaz; Stephen M Pastores; Debra A Goldman; Natalie Kostelecky; Richard F Tizon; Kay See Tan; Neil A Halpern
Journal:  Support Care Cancer       Date:  2019-12-14       Impact factor: 3.603

8.  Comorbidity and survival after admission to the intensive care unit: A population-based study of 41,230 patients.

Authors:  Alasdair Simpson; Kathryn Puxty; Philip McLoone; Tara Quasim; Billy Sloan; David S Morrison
Journal:  J Intensive Care Soc       Date:  2020-04-15

9.  Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer.

Authors:  Andrew S Epstein; Andrew Yang; Lauren E Colbert; Louis P Voigt; Jason Meadows; Jessica I Goldberg; Leonard B Saltz
Journal:  J Intensive Care Med       Date:  2017-12-20       Impact factor: 3.510

10.  Clinical outcomes in patients with lung cancer admitted to intensive care units.

Authors:  Jinkyeong Park; Woo Jin Kim; Ji Young Hong; Yoonki Hong
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.